Home > Journals > Minerva Anestesiologica > Past Issues > Minerva Anestesiologica 2015 November;81(11) > Minerva Anestesiologica 2015 November;81(11):1229-43

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Cite this article as

 

REVIEWS   Freefree

Minerva Anestesiologica 2015 November;81(11):1229-43

Copyright © 2015 EDIZIONI MINERVA MEDICA

language: English

Periprocedural management of antithrombotic therapy and open issues in cancer patients

Cuomo A. 1, Cascella M. 1, Bifulco F. 1, Marracino M. 1, Di Minno G. 2, Cerbone A. M. 2

1 Division of Anesthesia, Intensive Care and Pain Therapy Unit, Istituto Nazionale Tumori “Fondazione G. Pascale” - IRCCS, Naples, Italy; 2 Department of Clinical Medicine and Surgery, Reference Center for Hemorrhagic and Thrombotic Diseases, Federico II University, Naples, Italy


PDF


Perioperative management of patients who are receiving anticoagulant or antiplatelet drugs and require surgical or invasive procedure is a dilemma for clinicians. The discontinuation exposes the patient to an exceedingly high risk of thromboembolism while there is an exceedingly high bleeding risk if antithrombotic therapy is continued, strictly related to the type of surgery. This complex management is based on the assessment of thromboembolic and bleeding risk. In this review we analyze the strategies to optimize the perioperative use of antithrombotic drugs with special attention to new oral anticoagulant drugs, also in cancer patients.

top of page